In addition, a mouse model study showed that, at the two-time points of onset of NASH progression and HCC survival, combined treatment with pemafibrate and tofogliflozin (an SGLT-2 inhibitor) not only significantly relieved hyperglycemia and hypertriglyceridemia but also reduced ballooning of hepatocytes, reduced expression of ER stress-related genes level (such as Ire1a, Grp78, Xbp1, and Phlda3), and significantly improved the survival rate and decreased the tumors' numbers in the liver. Here, SLC5A2 is linked to hepatocellular carcinoma.